Special Issue "Graphene-Based Materials for Cancer Therapy"

A special issue of Nanomaterials (ISSN 2079-4991).

Deadline for manuscript submissions: 15 July 2020.

Special Issue Editors

Prof. Daniela Iannazzo
Website
Guest Editor
Department of Engineering, University of Messina, Contrada Di Dio, I-98166 Messina, Italy
Interests: Organic Synthesis; Advanced synthetic methodologies for the organic functionalization of nanomaterials for applications in drug delivery, biosensors, tissue engineering and in environmental field.
Prof. Dr. Alessandro Pistone
Website
Guest Editor
Department of Engineering, University of Messina, Messina, Italy
Interests: nanomaterials; drug delivery systems; tissue engineering; biomaterials
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Graphene-based nanomaterials such as fullerenes, carbon nanotubes graphene oxide, and graphene quantum dots have shown great potential in revolutionizing the future of nanomedicine and biotechnology. Their outstanding physical and chemical properties and the presence of more reactive groups on the graphene surface, which allow the multimodal conjugation with different functional groups and biologically active molecules, make them ideal candidates for cancer diagnosis and treatment. These nanomaterials have been conjugated with drugs and also labeled with tumor-targeting ligands, which are able to specifically recognize cancer receptors exposed on cancer cells, thus allowing a more efficient targeted delivery of anticancer agents while minimizing their distribution in healthy tissues. Graphene-based materials have been also investigated for the development of new imaging agents for the in vitro and in vivo diagnosis of several types of cancer as well as for the development of biosensors for the identification of specific cancer bio-markers. “Graphene-based materials for cancer therapy” aims at collecting full papers communications and reviews that prominently demonstrate the continuous efforts in developing advanced, graphene-based nanomaterials for cancer treatment and diagnosis. This Special Issue aims to cover a broad range of subjects, from nanomaterials synthesis to the design and development of nanostructures to be used as drug delivery systems, biosensors, and imaging agents for cancer treatment.

Prof. Daniela Iannazzo
Prof. Alessandro Pistone
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nanomaterials is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • graphene-based materials
  • anticancer therapy
  • drug delivery systems
  • imaging agents
  • biosensors

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

Open AccessArticle
Dual pH- and GSH-Responsive Degradable PEGylated Graphene Quantum Dot-Based Nanoparticles for Enhanced HER2-Positive Breast Cancer Therapy
Nanomaterials 2020, 10(1), 91; https://doi.org/10.3390/nano10010091 - 02 Jan 2020
Cited by 1
Abstract
Dual stimuli-responsive degradable carbon-based nanoparticles (DS-CNPs) conjugated with Herceptin (HER) and polyethylene glycol (PEG) have been designed for the treatment of HER2-positive breast cancer. Each component has been linked through disulfide linkages that are sensitive to glutathione in a cancer microenvironment. β-cyclodextrin (β-CD) [...] Read more.
Dual stimuli-responsive degradable carbon-based nanoparticles (DS-CNPs) conjugated with Herceptin (HER) and polyethylene glycol (PEG) have been designed for the treatment of HER2-positive breast cancer. Each component has been linked through disulfide linkages that are sensitive to glutathione in a cancer microenvironment. β-cyclodextrin (β-CD) on the surface of DS-CNPs formed an inclusion complex (DL-CNPs) with doxorubicin (DOX) at a high loading capacity of 5.3 ± 0.4%. In response to a high level of glutathione (GSH) and low pH in a tumor environment, DL-CNPs were rapidly degraded and released DOX in a controlled manner via disruption of host–guest inclusion. These novel DL-CNPs exhibited high cellular uptake with low toxicity, which induced the efficient inhibition of antitumor activity both in vitro and in vivo. Cell viability, confocal laser scanning microscopy, and animal studies indicate that DL-CNPs are a great platform with a synergistically enhanced antitumor effect from the dual delivery of HER and DOX in DL-CNPs. Full article
(This article belongs to the Special Issue Graphene-Based Materials for Cancer Therapy)
Show Figures

Graphical abstract

Open AccessArticle
A Smart Nanovector for Cancer Targeted Drug Delivery Based on Graphene Quantum Dots
Nanomaterials 2019, 9(2), 282; https://doi.org/10.3390/nano9020282 - 18 Feb 2019
Cited by 12
Abstract
Graphene quantum dots (GQD), the new generation members of graphene-family, have shown promising applications in anticancer therapy. In this study, we report the synthesis of a fluorescent and biocompatible nanovector, based on GQD, for the targeted delivery of an anticancer drug with benzofuran [...] Read more.
Graphene quantum dots (GQD), the new generation members of graphene-family, have shown promising applications in anticancer therapy. In this study, we report the synthesis of a fluorescent and biocompatible nanovector, based on GQD, for the targeted delivery of an anticancer drug with benzofuran structure (BFG) and bearing the targeting ligand riboflavin (RF, vitamin B2). The highly water-dispersible nanoparticles, synthesized from multi-walled carbon nanotubes (MWCNT) by prolonged acidic treatment, were linked covalently to the drug by means of a cleavable PEG linker while the targeting ligand RF was conjugated to the GQD by π–π interaction using a pyrene linker. The cytotoxic effect of the synthesized drug delivery system (DDS) [email protected] was tested on three cancer cell lines and this effect was compared with that exerted by the same nanovector lacking the RF ligand (GQD-PEG-BFG) or the anticancer drug ([email protected]). The results of biological tests underlined the low cytotoxicity of the GQD sample and the cytotoxic activity of the DDS against the investigated cancer cell lines with a higher or similar potency to that exerted by the BFG alone, thus opening new possibilities for the use of this drug or other anticancer agents endowed of cytotoxicity and serious side effects. Full article
(This article belongs to the Special Issue Graphene-Based Materials for Cancer Therapy)
Show Figures

Graphical abstract

Review

Jump to: Research

Open AccessReview
Graphene Oxide-Based Biosensors for Liquid Biopsies in Cancer Diagnosis
Nanomaterials 2019, 9(12), 1725; https://doi.org/10.3390/nano9121725 - 03 Dec 2019
Abstract
Liquid biopsies use blood or urine as test samples, which are able to be continuously collected in a non-invasive manner. The analysis of cancer-related biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNA, and exosomes provides important information in early [...] Read more.
Liquid biopsies use blood or urine as test samples, which are able to be continuously collected in a non-invasive manner. The analysis of cancer-related biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), microRNA, and exosomes provides important information in early cancer diagnosis, tumor metastasis detection, and postoperative recurrence monitoring assist with clinical diagnosis. However, low concentrations of some tumor markers, such as CTCs, ctDNA, and microRNA, in the blood limit its applications in clinical detection and analysis. Nanomaterials based on graphene oxide have good physicochemical properties and are now widely used in biomedical detection technologies. These materials have properties including good hydrophilicity, mechanical flexibility, electrical conductivity, biocompatibility, and optical performance. Moreover, utilizing graphene oxide as a biosensor interface has effectively improved the sensitivity and specificity of biosensors for cancer detection. In this review, we discuss various cancer detection technologies regarding graphene oxide and discuss the prospects and challenges of this technology. Full article
(This article belongs to the Special Issue Graphene-Based Materials for Cancer Therapy)
Show Figures

Figure 1

Back to TopTop